Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.
Sabina SangheraS MohiuddinJ CoastK GarfieldS NobleC MetcalfeJ A LaneE L TurnerD NealF C HamdyR M MartinJ L Donovannull nullPublished in: BMC cancer (2020)
Current Controlled Trials number, ISRCTN20141297: http://isrctn.org (14/10/2002); ClinicalTrials.gov number, NCT02044172: http://www.clinicaltrials.gov (23/01/2014).